2 results
Approved WMOCompleted
The purpose of this studie is to evaluate the bioequivalence of canagliflozin.
Approved WMOCompleted
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.